Market Access Impact EU5 [Growth Hormone Deficiency] [Report Updated: 01062017] Prices from USD $5145

05:29 EDT 1 Jul 2017 | BioPortfolio Report Blog

Market barriers may be costing you share, but perception could be the bigger problem

Market barriers affect nearly 25% of growth hormone prescriptions in the EU5 countries. Most brands lose market share because of them, but for some brands, perception may be an even bigger problem. As many as 16% of the doctors we surveyed either wouldn't prescribe these brands, or simply haven't heard of them at all.

Find out how doctors see your brand, and whether market barriers are dragging your market share down, in Market Access Impact: GHD EU5.

Based on a survey of 150 adult and paediatric endocrinologists, the report covers 7 major therapies from Eli Lilly, Ipsen, Ferring, Merck KGaA, Novo Nordisk, Pfizer, and Sandoz. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.

Top Takeaways

Most brands lose out: While every brand wins and loses share because of barriers, 5 of the 7 surveyed brands see a net loss.
One brand runs the table: The 3rd place brand sees a net share gain from every other surveyed brand, but without barriers, it would take a big hit and drop to 4th place.
No one barrier is to blame: Most of the 7 barriers covered in the report affect the same amount of prescriptions.
Doctors experience few barriers with each brand: Over 75% of surveyed doctors experience at most one barrier with any given brand.
Some brands are hit harder by certain barriers: Learn which brand doctors have the most trouble reimbursing, which three lose out due to patient type recommendations, and more.
Three drugs have a perception problem: Up to 16% of doctors either wouldn't consider prescribing these brands, or haven't heard of them at all.

Insight into 7 Major GHD Treatments

Genotropin somatropin; Pfizer
Humatrope somatropin; Eli Lilly
Norditropin somatropin; Novo Nordisk
NutropinAq somatropin; Ipsen
Omnitrope somatropin; Sandoz
Saizen somatropin; Merck KGaA
Zomacton somatropin; Ferring

Exploring Market Access Barriers

Market Access Impact: GHD EU5 explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?

How barriers affect your brand:

How many doctors prescribe your brand? How many don't, but would consider it?
Why don't doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 medical adult and paediatric endocrinologists30 from each EU5 country France, Italy, Germany, Spain, UKchosen from the largest community of validated physicians in the world.

All respondents have:

Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with GHD in total in the last month

We conducted the survey between May 2nd and 10th, 2017.


At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Original Article: Market Access Impact EU5 [Growth Hormone Deficiency] [Report Updated: 01062017] Prices from USD $5145


More From BioPortfolio on "Market Access Impact EU5 [Growth Hormone Deficiency] [Report Updated: 01062017] Prices from USD $5145"

Quick Search


Relevant Topics

Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...